Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion.
Zenan WangBinghao LiShan LiWenlong LinZhan WangShengdong WangWeida ChenWei ShiTao ChenHao ZhouEloy YinwangWenkan ZhangHaochen MouXupeng ChaiJiahao ZhangZhimin LuZhao-Ming YePublished in: Nature communications (2022)
Chemotherapy elicits tumor immune evasion with poorly characterized mechanisms. Here, we demonstrate that chemotherapy markedly enhances the expression levels of CD47 in osteosarcoma tissues, which are positively associated with patient mortality. We reveal that macrophages in response to chemotherapy secrete interleukin-18, which in turn upregulates expression of L-amino acid transporter 2 (LAT2) in tumor cells for substantially enhanced uptakes of leucine and glutamine, two potent stimulators of mTORC1. The increased levels of leucine and enhanced glutaminolysis activate mTORC1 and subsequent c-Myc-mediated transcription of CD47. Depletion of LAT2 or treatment of tumor cells with a LAT inhibitor downregulates CD47 with enhanced macrophage infiltration and phagocytosis of tumor cells, and sensitizes osteosarcoma to doxorubicin treatment in mice. These findings unveil a mutual regulation between macrophage and tumor cells that plays a critical role in tumor immune evasion and underscore the potential to intervene with the LAT2-mediated amino acid uptake for improving cancer therapies.
Keyphrases
- amino acid
- poor prognosis
- locally advanced
- nk cells
- binding protein
- adipose tissue
- squamous cell carcinoma
- skeletal muscle
- type diabetes
- living cells
- replacement therapy
- young adults
- oxidative stress
- risk factors
- single cell
- cardiovascular disease
- dna methylation
- endoplasmic reticulum stress
- fluorescent probe
- chemotherapy induced